It binds to components of the complement alternative pathway C3 convertase and does not inhibit any of the classical pathway's ability to produce C3a, C5a, C3b, C5b and C5b-9 and is produced only by the complement alternative pathway A method of treating a hemolytic disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody that selectively inhibits C3a, C5a, C3b, C5b and C5b-9 . [Selection] Figure 1C3a、C5a、C3b、C5bおよびC5b-9を産生する古典的経路の能力のいずれも阻害することなく、補体第2経路C3転換酵素の成分に結合し、補体第2経路によってのみ産生されるC3a、C5a、C3b、C5bおよびC5b-9を選択的に阻害する治療上有効量の抗体を、被験体に投与することを含む、それを必要とする被験体における溶血性障害を治療する方法。【選択図】図１
